Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Not yet recruiting 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Head & Neck 4Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 31Colorectal Neoplasms 18Carcinoma, Hepatocellular 18Stomach Neoplasms 12Esophageal Squamous Cell Carcinoma 12Squamous Cell Carcinoma of Head and Neck 9Neoplasm Metastasis 9Advanced Solid Tumor 9Lung Neoplasms 7Head and Neck Neoplasms 7Rectal Neoplasms 5Esophageal Neoplasms 5Small Cell Lung Carcinoma 4Neoplasms 4Nasopharyngeal Carcinoma 4Melanoma 4Solid Tumor 3Lymphoma, Follicular 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Biliary Tract Neoplasms 3Adenocarcinoma 3Triple Negative Breast Neoplasms 2Recurrence 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma 2Hodgkin Disease 2

Interventions

Cisplatin 32Gemcitabine 21Radiotherapy, Intensity-Modulated 16toripalimab 14Capecitabine 11Magnetic Resonance Spectroscopy 10Specimen Handling 9Radiotherapy 7Drug Therapy 7pembrolizumab 6Platinum 6Nivolumab 6Immune Checkpoint Inhibitors 61,2-diaminocyclohexaneplatinum II citrate 6Docetaxel 5tislelizumab 4spartalizumab 4camrelizumab 4sintilimab 3anlotinib 3Immunoglobulin G 3Disulfides 3Carboplatin 3nimotuzumab 2fludarabine 2atezolizumab 2Taxes 2Radiation 2Phantoms, Imaging 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Nasopharyngeal Carcinoma × tislelizumab × 1 year × Clear all
NCT05211232 2026-05-29

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 3 Active not recruiting
450 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT07388758 2026-02-05

Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 2 Not yet recruiting
37 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT07331428 2026-01-09

MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC

Fujian Cancer Hospital

Phase 2 Not yet recruiting
25 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT04215978 2025-10-03

Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

BeiGene

Phase 1 Completed
204 enrolled
Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡